Turn Therapeutics Inc. (NASDAQ:TTRX) Short Interest Down 51.9% in June

Turn Therapeutics Inc. (NASDAQ:TTRX) saw a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 30,684 shares, a decline of 51.9% from the May 31st total of 63,729 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily volume of 72,651 shares, the short-interest ratio is presently 0.4 days.

Hedge Funds Weigh In On Turn Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Hodges Capital Management Inc. acquired a new stake in Turn Therapeutics during the 4th quarter worth about $39,000. LPL Financial LLC acquired a new stake in Turn Therapeutics during the fourth quarter worth approximately $51,000. Tamar Securities LLC bought a new stake in Turn Therapeutics in the fourth quarter worth approximately $59,000. Composition Wealth LLC bought a new stake in Turn Therapeutics in the fourth quarter worth approximately $63,000. Finally, Jane Street Group LLC acquired a new position in Turn Therapeutics in the fourth quarter valued at approximately $68,000.

Wall Street Analysts Forecast Growth

Separately, D. Boral Capital reissued a “buy” rating and set a $8.00 target price on shares of Turn Therapeutics in a report on Tuesday, March 24th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Turn Therapeutics Trading Up 6.2%

Shares of TTRX traded up $0.42 during mid-day trading on Tuesday, reaching $7.33. 42,677 shares of the company were exchanged, compared to its average volume of 36,880. Turn Therapeutics has a 52 week low of $2.57 and a 52 week high of $26.50. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.23 and a current ratio of 2.23. The stock has a market capitalization of $218.51 million and a PE ratio of -38.53. The business has a 50 day simple moving average of $4.94 and a two-hundred day simple moving average of $4.14.

Turn Therapeutics (NASDAQ:TTRX) last announced its earnings results on Monday, May 11th. The company reported ($0.03) EPS for the quarter.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.